ADVERTISEMENT
2 /3 FREE ARTICLES LEFT THIS MONTH Remaining
Chemistry matters. Join us to get the news you need.

If you have an ACS member number, please enter it here so we can link this account to your membership. (optional)

ACS values your privacy. By submitting your information, you are gaining access to C&EN and subscribing to our weekly newsletter. We use the information you provide to make your reading experience better, and we will never sell your data to third party members.

ENJOY UNLIMITED ACCES TO C&EN

Business

Lilly, Bayer help animal health deal

by Ann M. Thayer
January 9, 2017 | APPEARED IN VOLUME 95, ISSUE 2

[+]Enlarge
Credit: Shutterstock
Lilly is acquiring a portfolio that includes vaccines for pets.
Credit: Shutterstock
Lilly is acquiring a portfolio that includes vaccines for pets.

Eli Lilly & Co. has spent $885 million to buy three animal vaccine product lines in the U.S. from Boehringer Ingelheim, along with a manufacturing and R&D site. Meanwhile, Bayer is acquiring two parasite control products. The U.S. Federal Trade Commission required Boehringer to divest the businesses to complete a $13.5 billion swap of its consumer health business for Sanofi’s animal health subsidiary Merial on Jan 1. Last year, France’s Ceva Santé Animale bought nine Merial products to address European regulatory concerns.

X

Article:

This article has been sent to the following recipient:

Leave A Comment

*Required to comment